Market Size of Proliferative Diabetic Retinopathy Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 9.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Proliferative Diabetic Retinopathy Market Analysis
The Proliferative Diabetic Retinopathy Market is expected to register a CAGR of 9.4% during the forecast period. Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina. Some of the signs and symptoms are progressive loss of vision, fine to severe loops of new vessels that may grow on the optic disc and these new vessels may leak and resulting in retinal edema and so on. The major risk factors for proliferative diabetic retinopathy (PDR) include the duration of diabetes, for 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of proliferative diabetic retinopathy (PDR).
According to the International Agency for the Prevention of Blindness, low- and middle-income countries account for approximately 75% of the global diabetes burden, yet many people are ill-equipped to properly identify, treat and manage this disease. Furthermore, as per the study published in the Ophthalmological Journal, estimates diabetic retinopathy affects 1 in 3 people with diabetes and by the year 2040, diabetes is projected to affect 642 million adults.
Growth in the geriatric population increases the prevalence of diabetes and diabetic retinopathy and the availability of advanced technology and minimally invasive laser technique are the key driving factors in the proliferative diabetic retinopathy market.
Proliferative Diabetic Retinopathy Industry Segmentation
Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative Diabetic Retinopathy Market is segmented By Treatment Type and Geography.
| By Treatment Type | |
| Anti-VEGF Agents | |
| Corticosteroids | |
| Laser Surgery | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Proliferative Diabetic Retinopathy Market Size Summary
The proliferative diabetic retinopathy market is poised for significant growth, driven by the increasing prevalence of diabetes and the advancements in medical technology. Proliferative diabetic retinopathy, a severe complication of diabetes, involves the growth of new blood vessels on the retina, which can lead to vision loss if untreated. The condition is more prevalent in individuals with a long history of diabetes, and its incidence is rising, particularly in low- and middle-income countries where diabetes management is often inadequate. The geriatric population's growth further exacerbates this trend, as older adults are more susceptible to diabetes and its complications. The market is characterized by the availability of advanced technologies and minimally invasive treatments, which are crucial in managing this condition effectively.
The anti-VEGF agents segment holds a significant portion of the market share, attributed to their effectiveness in improving visual acuity in patients with proliferative diabetic retinopathy. This segment is expected to maintain its prominence due to the rising prevalence of diabetic retinopathy and the ongoing advancements in treatment options. North America is anticipated to dominate the global market, supported by a high prevalence of diabetes and well-established healthcare infrastructure. The market is consolidated, with a few major players like Novartis AG, Regeneron Pharmaceuticals Inc, and Allergan Plc leading the industry. These companies are pivotal in shaping the market dynamics through their innovative treatment solutions and strategic initiatives.
Proliferative Diabetic Retinopathy Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Diabetes Increases Risk of Diabetic Retinopathy
-
1.2.2 Availability of Advanced Technology and Minimally Invasive Laser Technique
-
-
1.3 Market Restraints
-
1.3.1 Extended Approval Time for Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Treatment Type
-
2.1.1 Anti-VEGF Agents
-
2.1.2 Corticosteroids
-
2.1.3 Laser Surgery
-
2.1.4 Others
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle-East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle-East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Proliferative Diabetic Retinopathy Market Size FAQs
What is the current Proliferative Diabetic Retinopathy Market size?
The Proliferative Diabetic Retinopathy Market is projected to register a CAGR of 9.40% during the forecast period (2024-2029)
Who are the key players in Proliferative Diabetic Retinopathy Market?
Novartis AG, Regeneron Pharmaceuticals Inc, Allergan Plc, Hoffmann-La Roche (Genentech) and Oxurion NV are the major companies operating in the Proliferative Diabetic Retinopathy Market.
